NEVVI Medicare utilization intelligence

← back

BATTINI, RAMAKRISHNAM.D. NPI 1710122601 Clinician

Hematology-Oncology · GERMANTOWN, TN

Specialty Hematology-Oncology — from billed Medicare claims
In practice about 23 years since medical school (class of 2003, self-reported to CMS)
Location GERMANTOWN, TN · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 91 codes billed · 121,451 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
THE WEST CLINIC P.C.
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2018-09

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9299 Injection, nivolumab, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J9263 Injection, oxaliplatin, 0.5 mg
J0897 Injection, denosumab, 1 mg
J9171 Injection, docetaxel, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9267 Injection, paclitaxel, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1449 Injection, eflapegrastim-xnst, 0.1 mg
Q5107 Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
J1437 Injection, ferric derisomaltose, 10 mg
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
80048 Blood test, basic group of blood chemicals (calcium, total)
80076 Liver function blood test panel
J0640 Injection, leucovorin calcium, per 50 mg
J2469 Injection, palonosetron hcl, 25 mcg
J9041 Injection, bortezomib, 0.1 mg
36415 Insertion of needle into vein for collection of blood sample
J0461 Injection, atropine sulfate, 0.01 mg
J9190 Injection, fluorouracil, 500 mg
J0894 Injection, decitabine, 1 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
96413 Administration of chemotherapy into vein, 1 hour or less
J2919 Injection, methylprednisolone sodium succinate, 5 mg
88185 Flow cytometry technique for dna or cell analysis, each additional marker
82784 Gammaglobulin (immune system protein) measurement
J2405 Injection, ondansetron hydrochloride, per 1 mg
J9045 Injection, carboplatin, 50 mg
J9395 Injection, fulvestrant, 25 mg
J3480 Injection, potassium chloride, per 2 meq
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
J9206 Injection, irinotecan, 20 mg
83883 Nephelometry, test method using light
96372 Injection of drug or substance under skin or into muscle
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
83540 Iron level
83550 Iron binding capacity
96375 Injection of additional new drug or substance into vein
82728 Ferritin (blood protein) level
96417 Administration of additional new drug or substance into vein, 1 hour or less
J3475 Injection, magnesium sulfate, per 500 mg
82565 Blood creatinine level
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96415 Administration of chemotherapy into vein, each additional hour
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
83735 Magnesium level
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J1200 Injection, diphenhydramine hcl, up to 50 mg
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
83615 Lactate dehydrogenase (enzyme) level
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
84443 Blood test, thyroid stimulating hormone (tsh)
85610 Blood test, clotting time
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
82378 Carcinoembryonic antigen (cea) protein level
J3490 Unclassified drugs
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
J1454 Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
J3489 Injection, zoledronic acid, 1 mg
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
97140 Therapy procedure using manual technique, each 15 minutes
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
84100 Phosphate level
86301 Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9
82607 Cyanocobalamin (vitamin b-12) level
82746 Folic acid level, serum
82947 Blood glucose (sugar) level
85045 Red blood count, automated test
J7030 Infusion, normal saline solution , 1000 cc
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96361 Infusion into a vein for hydration, each additional hour
96411 Administration of additional new drug or substance into vein using push technique
97535 Training for self-care or home management, each 15 minutes
84550 Uric acid level, blood
97110 Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes
96360 Infusion into a vein for hydration, 31-60 minutes
97530 Therapy procedure using functional activities
88184 Flow cytometry technique for dna or cell analysis, first marker
82232 Beta-2 microglobulin (protein) level
86431 Rheumatoid factor level
88189 Flow cytometry technique for dna or cell analysis, 16 or more markers
90653 Influenza vaccine, inactivated
G0008 Administration of influenza virus vaccine
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.